The treatment of AML with the NPM1 mutation traditionally includes intensive induction chemotherapy or low-intensive chemotherapy with HMA and VEN, followed by consolidation and/or allogeneic stem cell transplantation, although patients who achieve MRD negative CR can attain long-term survival without allo-HSCT. This evidence concerns the gene NPM1 and acute myeloid leukemia.